New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2013
16:20 EDTCTB, GT, LYV, ULTA, HMA, BIIB, VODOn The Fly: Closing Wrap
Stocks on Wall Street were lower despite opening sharply higher as the market looked to avoid its first three day losing streak of the year. Downside momentum quickly took hold however, and the averages moved steadily lower through the session, moving to their lows in the final hour of trading but finishing just off those levels. ECONOMIC EVENTS: In the U.S., the MBA's purchase applications composite index rose 5.0% for the week. The U.S. posted a $139B May budget deficit against expectations for a $130B deficit, and compared to a $124.6B deficit a year ago. In Europe, factory production in the 17-nation euro area rose 0.4% in April from March, compared to expectations for it to remain unchanged. COMPANY NEWS: Cooper Tire (CTB) agreed to be acquired by India's Apollo Tyres for $35.00 per share in cash, or $2.5B. Cooper shares surged $10.10, or 41.12%, to $34.66 to trade near $34.50 following the deal announcement, while peer Goodyear Tire (GT) advanced about 33c, or 2.26%, to $14.93... Live Nation (LYV) shares gained $2.33, or 16.84%, to $16.17 after the company announced it prevailed in an arbitration ruling related to a ticketing license software agreement... MAJOR MOVERS: Among the notable gainers was Ulta Salon (ULTA), up $12.51, or 14.87%, to $96.64 following its quarterly earnings report. Also higher was Health Management (HMA), up $1.58, or 11.34%, to $15.51 after Glenview Capital said in a filing it is seeking to repeal a provision that prevents entities from holding more than 15% of the company's stock and saying it would look to nominate candidates to the company's board. Among noteworthy losers was Biogen (BIIB), down $16.48, or 7.39%, to $206.55 after the stock was downgraded to Neutral from Buy at Citigroup, which cited concerns that EU medical regulators are unlikely to approve the company's multiple sclerosis treatment. Also lower were U.S.-listed shares of Vodafone (VOD), down 71c, or 2.47%, to $28.12 after the company confirmed it approached Kabel Deutschland about a possible deal. INDICES: The Dow was down 126.79, or 0.84%, to 14,995.23; the S&P 500 was down 13.61, or 0.84%, to 1,612.52; the Nasdaq was down 36.52, or 1.06%, to 3,400.43.
News For CTB;GT;LYV;ULTA;HMA;BIIB;VOD From The Last 14 Days
Check below for free stories on CTB;GT;LYV;ULTA;HMA;BIIB;VOD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2014
06:24 EDTBIIBBiogen price target raised to $387 from $343 at Citigroup
Citigroup raised its price target for Biogen shares to $387 citing the company's earnings and revenue growth following its better than expected Q2 results. Citi keeps a Buy rating on the stock.
July 23, 2014
11:43 EDTBIIBBiogen announces PLEGRIDY EC approval
Subscribe for More Information
10:25 EDTBIIBBiogen price target raised to $420 from $370 at Piper Jaffray
Subscribe for More Information
10:02 EDTGT, CTBOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:50 EDTBIIBBiogen says strategic bias still tuck-in acquisitions
Subscribe for More Information
09:37 EDTBIIBBiogen says 'clearly' has considered tax inversion
Subscribe for More Information
09:25 EDTBIIBBiogen sees Japan as an attractive growth opportunity for company
Says remains committed to SG&A leverage in 2014. Says guidance assumes Tecfidera EU uptake similar to U.S.
09:17 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
09:05 EDTBIIBBiogen says received letter from EU saying PLEGRIDY has been approved
Subscribe for More Information
08:56 EDTBIIBBiogen still sees FY CapEx approximately $300M
Believes TECFIDERA is on track to become the leading MS product in the U.S. Says outside the U.S., demand for TECFIDERA has been broad; launch trajectories similar to experience in U.S. Continues to be in discussions with AIFA to resolve its dispute on Tysabri for February 2009-January 2013. Says FY guidance "meaningfully increased" due primarily to the  growth  of  TECFIDERA in the U.S. and the EU., the strength of our other MS therapies and clarity on the AIFA pricing matter. Comments from slides that will be presented on the Q2 earnings conference call.
06:55 EDTCTBCooper Tire initiated with a Neutral at JPMorgan
Subscribe for More Information
06:54 EDTGTGoodyear Tire initiated with an Overweight at JPMorgan
Target $38.
06:50 EDTBIIBBiogen raises FY14 EPS to $12.90-$13.10 from $11.35-$11.45, consensus $11.53
Subscribe for More Information
06:48 EDTBIIBBiogen reports Q2 Tecfidera revenue $700M; Reports Q2 Avonex revenue $774M
Subscribe for More Information
06:47 EDTBIIBBiogen reports Q2 adjusted EPS $3.49, consensus $2.83
Reports Q2 revenue $2.42B, consensus $2.16B; Non-GAAP diluted EPS was benefited by approximately 15c, following the approval from an agreement with the Italian National Medicines Agency relating to Tysabri sales in Italy.
July 22, 2014
14:30 EDTBIIBBiogen technical remarks ahead of earnings
Subscribe for More Information
09:13 EDTCTBCooper Tire gaining back lost market shares, says Northcoast
Subscribe for More Information
July 21, 2014
13:18 EDTULTAUlta Salon mentioned positively at ITG Research
Subscribe for More Information
07:37 EDTBIIBBiogen July weekly volatility elevated into Q2 and outlook
Biogen July weekly call option implied volatility is at 55, August is at 34, October is at 36; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q2 on July 23.
July 16, 2014
07:18 EDTVODVodafone head says unlikely interested in America Movil assets, Reuters says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use